Ofatumumab for difficult-to-treat narcolepsy type 1
Treatments studied
This study tests a medication called ofatumumab, which may reduce the immune system attack that causes narcolepsy type 1. It is for people who have not responded to standard treatments and aims to improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 10 and 60 years old.
- You have been diagnosed with narcolepsy type 1.
- You have tried standard treatments and they did not help or stopped working, or you chose not to take medication.
- You are willing to have a lumbar puncture (spinal tap) and blood tests.
- You do not have other serious health conditions or active infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
This study looks at whether blood tests and eye-tracking tasks can show how well ofatumumab slows or stops MS damage. It's for people starting ofatumumab as part of their regular care who have active relapsing-remitting MS.
Hear when a new Narcolepsy Type 1 (NT1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.